PhytoCeutica, Inc.

5 Science Park, Suite 13

New Haven, CT  06511

 

Phone: 203-777-3462

Fax: 203-777-3538

E-mail: info@phytoceutica.com

>  Clinical Program Home

___________________________________________________

>  PHY906 in Liver Cancer

>  PHY906 in Colorectal Cancer

>  Upcoming Clinical Trials

_____________________________________________

 

 

 

 

Title:

 

 

                        

Objectives:

 

 

 

 

Enrollment:

 

Sites:

 

 

 

Details:

 

 

 

 

 

A Phase I/II, Multicenter, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced, Unresectable Hepatocellular Carcinoma

 

(a) Determining maximum tolerated dose of PHY906 + capecitabine (phase I)

(b) Determining objective antitumor response rate, including time to disease progression, overall survival time, etc. (phase II)

 

Active enrollment; commenced November 2003

 

(1) City of Hope National Medical Center, Duarte, California

(2) Stanford University School of Medicine, Palo Alto, California

(3) VA Connecticut Heathcare System, West Haven, Connecticut

 

If you are a patient and would like to obtain more information on the study, please refer to the listing provided by the U.S. National Institutes of Health or you may contact us at info@phytoceutica.com.

PHY906 in Liver Cancer (Hepatocellular Carcinoma)